570 related articles for article (PubMed ID: 30209859)
1. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.
Matveeva OV; Chumakov PM
Rev Med Virol; 2018 Nov; 28(6):e2008. PubMed ID: 30209859
[TBL] [Abstract][Full Text] [Related]
2. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
3. The pros and cons of interferons for oncolytic virotherapy.
Geoffroy K; Bourgeois-Daigneault MC
Cytokine Growth Factor Rev; 2020 Dec; 56():49-58. PubMed ID: 32694051
[TBL] [Abstract][Full Text] [Related]
4. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
5. The gamble between oncolytic virus therapy and IFN.
Li Q; Tan F; Wang Y; Liu X; Kong X; Meng J; Yang L; Cen S
Front Immunol; 2022; 13():971674. PubMed ID: 36090998
[TBL] [Abstract][Full Text] [Related]
6. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
7. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.
Sobol PT; Hummel JL; Rodrigues RM; Mossman KL
Gene Ther; 2009 Sep; 16(9):1077-87. PubMed ID: 19474810
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of innate immune signaling pathways in transformed cells.
Heiber JF; Barber GN
Methods Mol Biol; 2012; 797():217-38. PubMed ID: 21948479
[TBL] [Abstract][Full Text] [Related]
10. Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.
Ebrahimi S; Ghorbani E; Khazaei M; Avan A; Ryzhikov M; Azadmanesh K; Hassanian SM
J Cell Biochem; 2017 Aug; 118(8):1994-1999. PubMed ID: 28135008
[TBL] [Abstract][Full Text] [Related]
11. [Oncolytic enteroviruses].
Chumakov PM; Morozova VV; Babkin IV; Baĭkov IK; Netesov SV; Tikunova NV
Mol Biol (Mosk); 2012; 46(5):712-25. PubMed ID: 23156670
[TBL] [Abstract][Full Text] [Related]
12. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
[TBL] [Abstract][Full Text] [Related]
13. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 and Interferon-α Signaling
Danziger O; Pupko T; Bacharach E; Ehrlich M
Front Immunol; 2018; 9():94. PubMed ID: 29441069
[TBL] [Abstract][Full Text] [Related]
18. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
[TBL] [Abstract][Full Text] [Related]
19. VSV-tumor selective replication and protein translation.
Barber GN
Oncogene; 2005 Nov; 24(52):7710-9. PubMed ID: 16299531
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.
Huang PY; Guo JH; Hwang LH
Mol Ther; 2012 Feb; 20(2):298-305. PubMed ID: 22068428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
